Vaxart (VXRT) announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine ...

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the ...

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine ...

On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.78 which represents a decrease of $-0.04 or -4.88% from the prior close of $0.82. The stock opened at $0.81 and touched a low of ...

On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.77 which represents a decrease of $-0.02 or -2.53% from the prior close of $0.79. The stock opened at $0.79 and touched a low of ...

400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine ...

400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA ...

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine ...

Vaxart (NASDAQ:VXRT), Inc., a biotechnology company focused on developing vaccines, announced today that it has terminated its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald ...

Vaxart, Inc. (NASDAQ:VXRT – Get Free Report) crossed below its two hundred day moving average during trading on Thursday .The stock has a two hundred day moving average of $0.83 and traded as ...

Vaxart, Inc., is a clinical-stage biotechnology company, announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at IDWeek taking place October ...